drugset / Trial / NCT00377325
The Effectiveness of Lower Cyclosporine Doses for Psoriasis
Phase 2
Withdrawn
University of Rochester
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collab
RandomizedFactorialQuadruple-blindTreatment
Summary
This study will evaluate whether lower doses of cyclosporine can cause fewer side effects and still produce the same beneficial results that are seen with a standard cyclosporine dose regimen when treating individuals with moderate to severe psoriasis.
Timeline
- Start
- 2007-06
- Primary completion
- 2013-06
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 4 mg/kg | — |